Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | VSIR | Q9H7M9 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421862 | 0.89 | NPSR1 (0.39) | — | |
| SCHEMBL31722879 | 0.84 | GLO1 (0.44) | CD274PDCD1LG2OPRD1OPRM1CTSC | |
| SCHEMBL29526133 | 0.82 | DPP4 (0.46) | CD274PDCD1LG2OPRD1OPRM1CTSC | |
| SCHEMBL29854499 | 0.82 | CD274 (0.52) | CD274PDCD1LG2OPRD1OPRM1MME | |
| SCHEMBL31707394 | 0.82 | ACE (0.44) | OPRD1OPRM1MMECTSC | |
| SCHEMBL31045832 | 0.82 | ACE (0.44) | OPRD1OPRM1MMECTSC | |
| SCHEMBL30567419 | 0.81 | OPRD1 (0.37) | CD274PDCD1LG2OPRD1OPRM1MME | |
| SCHEMBL31031520 | 0.81 | ALDH1A1 (0.39) | OPRD1MME | |
| SCHEMBL29526248 | 0.81 | DPP4 (0.48) | CD274PDCD1LG2OPRD1OPRM1CTSC | |
| SCHEMBL30894431 | 0.80 | ACE (0.43) | OPRD1OPRM1MMECTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250018014-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-01-16 | — | — | US | disclosed |
| US-20220125891-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250018014-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | RNASE1, IRAK1, SERBP1 | CD274 4377/4885PDCD1LG2 4188/4885OPRD1 3980/4885 |
| US-20220125891-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | RNASE1, IRAK1, SERBP1 | CD274 4377/4885PDCD1LG2 4188/4885OPRD1 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.